DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)

Market Cap	787.07B
Revenue (ttm)	869.00B
Net Income (ttm)	59.79B
Shares Out	44.39M
EPS (ttm)	1,344.35
PE Ratio	13.19
Forward PE	10.92
Dividend	200.00 (1.10%)
Ex-Dividend Date	Dec 27, 2024

Volume	293,686
Average Volume	237,687
Open	18,170
Previous Close	18,140
Day's Range	17,560 - 18,300
52-Week Range	14,400 - 20,450
Beta	0.34
RSI	41.25
Earnings Date	Nov 14, 2025

About DongKook Pharmaceutical

DongKook Pharmaceutical Co., Ltd. produces and sells pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, cosmetics, and other products. Its pipeline includes DKF-MB601, used to treat Hepatitis B; DKF-MB501, to treat obesity; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, indicated for benign prostatic hyperplasia; DKF-447, to treat diabetes; DKB-123, used for wound healing, tissue repair; and DKM-428, used ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1968
• Employees: 1,211
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086450

Financial Performance

In 2024, DongKook Pharmaceutical's revenue was 812.17 billion, an increase of 11.10% compared to the previous year's 730.99 billion. Earnings were 60.77 billion, an increase of 29.92%.